SESSION 2: MEMBER DISCUSSION
SESSION 6: DELIBERATION AND BIOETHICS EDUCATION: CASE STUDY OF PUBLIC HEALTH EMERGENCY RESPONSE (CONTINUED)
DR. GUTMANN: Welcome back, everybody. We are going to move on to our second speaker for Public Health Emergency Response, Dr. Anthony Fauci.
SESSION 5: DELIBERATION AND BIOETHICS EDUCATION: CASE STUDY OF PUBLIC HEALTH EMERGENCY RESPONSE
DR. GUTMANN: Good morning, everybody. I'm Amy Gutmann, President of the University of Pennsylvania and Chair of the Presidential Commission for the Study of Bioethical Issues.
SESSION 3: MEMBER DISCUSSION [CONSENT CAPACITY FRAMING AND POSSIBLE RECOMMENDATIONS]
SESSION 7: DELIBERATION AND BIOETHICS EDUCATION: OVERVIEW
DR. WAGNER: Folks, thank you for joining us. This panel is going to be a little more theoretical, less focused on a particular incident, and a little less applied. It will give us an overview of what deliberation of bioethics education can mean generally. And folks, the way we will work this is I will introduce you each, one at a time, and ask you to speak.
Do they have a ten minute time limit, also?
DR. GUTMANN: Yes.
DR. GUTMANN: Welcome everybody. I'm Amy Gutmann. I'm President of the University of Pennsylvania. And I'm Director and Chair of the Presidential Commission for the Study of Bioethical Issues. And on behalf of myself and our Vice Chair, Jim Wagner, and all of our Commission members, I'd like to welcome you to this, our nineteenth meeting. I will begin by noting the presence of our designated federal official, Bioethics Commission Executive Director Lisa M. Lee. Lisa, please stand up. Thank you.
DR. GUTMANN: So we are turning now to our third specific topic, Neuroscience and Law. And we can take this work in many directions. But certainly some fundamental questions that involve whether and how to use neuroscience technologies in the courtroom. For example, what can neuroscience in its current capacity tell us about whether any individual is legally blameworthy for his or her actions? What is the potential for neuroscience to answer this question?
DR. GUTMANN: We are blessed to have a great group of people presenting with expertise that is wide ranging in neuroscience, research, the ethics of neuroscience research and the ethics of the potential applications of the results of this research. And this is a unique opportunity for us as a Commission to hear from you. So give us one recommendation that you would like to see us, what we do in our report, whether it be what you want to make sure we attend to, something you think is really important for us to observe in the report.
SESSION 4: NEUROSCIENCE RESEARCH AND DIMINISHED CAPACITY
DR. GUTMANN: Great, this panel is going to revisit a topic that we discussed in our last meeting as well, and that is capacity to consent in research. And first we will hear from Dr. Jerry Menikoff, who is the director of the Office of Human Research Protections in the U.S. Department of Health and Human Services.
SESSION 3: NEUROSCIENCE RESEARCH—CLINICAL INNOVATION AND APPLICATIONS
DR. WAGNER: Welcome back everybody. I hope you enjoyed a good break over lunch. We are going to turn our attention now to clinical innovation and applications through neuroscience research. We are going to hear first ‑‑ same process, panelists. We are going to hear from each of you in rapid and fire sequence, and then have an opportunity to engage you with our questions from the panel.
This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply